The nitroreductase prodrug SN 28343 enhances the potency of systemically administered armed oncolytic adenovirus ONYX-411NTR
- 2 November 2007
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Gene Therapy
- Vol. 14 (12), 953-967
- https://doi.org/10.1038/sj.cgt.7701088
Abstract
Conditionally replicating adenoviruses (CRAd) ‘armed’ with prodrug-activating genes have the potential to augment the efficacy of virotherapy. An Escherichia coli nitroreductase (NTR) gene (nfsB) was introduced into the E3B region of the systemically active CRAd ONYX-411, to produce ONYX-411NTR, which had single agent oncolytic activity equivalent to unarmed virus in vitro and in vivo. A fluorogenic probe (SN 29884) developed to monitor NTR expression revealed robust, durable NTR expression in ONYX-411NTR infected neoplastic but not primary human cell lines. NTR expression occurred >24 h post-infection in parallel with fiber and was sensitive to ara-C indicating transcriptional linkage to viral replication. A novel NTR prodrug, the 3,5-dinitrobenzamide-2-bromomustard SN 27686, was shown to be more dose potent and selective than CB 1954 and provided a superior bystander effect in 3D multicellular layer cultures. Its water-soluble phosphate ester SN 28343 was substantially more active than CB 1954 against xenografts containing a minority of stable NTR-expressing cells. A single intravenous dose of ONYX-411NTR (108 PFU) to nude mice bearing large H1299 xenografts (>350 mm3) resulted in tumor-specific NTR expression which increased over time. Despite extensive viral spread by day 14, this conservative virus dose and schedule was unable to control such well-established tumors. However, subsequent administration of SN 28343 resulted in the majority of mice (62.5%) being tumor-free on day 120.This publication has 73 references indexed in Scilit:
- Adenovirus-Induced Extracellular Signal-Regulated Kinase Phosphorylation during the Late Phase of Infection Enhances Viral Protein Levels and Virus ProgenyCancer Research, 2006
- Aerobic 2- and 4-nitroreduction of CB 1954 by human liverToxicology, 2005
- Armed therapeutic viruses: Strategies and challenges to arming oncolytic viruses with therapeutic genesCancer Gene Therapy, 2002
- Viral OncolysisThe Oncologist, 2002
- Oncolytic biotherapy: a novel therapeutic platformThe Lancet Oncology, 2002
- Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954Cancer Gene Therapy, 2000
- The Hallmarks of CancerCell, 2000
- Phthalimide analogs of CB 1954Anti-Cancer Drugs, 1999
- Cancer Cell CyclesScience, 1996
- Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954European Journal Of Cancer, 1995